Topical minoxidil comes in two strengths: 2% and 5%. The intuitive assumption is that 5% is simply the better product — two and a half times the drug, so presumably more hair. Forums tend to treat 2% as the “weak” version for people who aren’t serious about hair loss.

The clinical trials tell a more interesting story. In men, 5% does outperform 2%, though by far less than the concentration gap implies. In women, the pooled evidence shows no reliable difference in regrowth between the two. The side-effect picture depends on the formula: as a solution, 5% causes more scalp irritation and more unwanted facial hair than 2%, but much of that irritation comes from the solvent, not the drug.

What the Head-to-Head Trials Show

In men: 5% wins, modestly

The key trial in men is Olsen et al. (2002), which randomized 393 men to 5% solution, 2% solution, or placebo for 48 weeks. Both strengths beat placebo. The 5% group produced roughly 45% more regrowth than the 2% group by hair count, and it worked faster. It also caused more itching and local irritation. This trial is the main reason 5% is the labeled standard for men.

Notice what “45% more” means: not 150% more, which is what the concentration ratio would suggest. Minoxidil’s dose-response flattens out. Past a certain point, more drug on the scalp mostly means more drug causing side effects.

In women: little to no difference

In women, the pivotal trial is Lucky et al. (2004), which compared 5% solution, 2% solution, and placebo in 381 women over 48 weeks. Both strengths beat placebo on hair count. The only measure where 5% was statistically superior to 2% was the women’s own rating of treatment benefit, not hair count or investigator assessment. The 5% group had more itching, local irritation, and unwanted facial hair.

A later trial changed the format rather than just the dose. Blume-Peytavi et al. (2011) compared 5% foam applied once daily with 2% solution applied twice daily in 113 women. The foam was non-inferior at 24 weeks and caused less itching and scalp irritation — a result that says as much about the vehicle and the routine as about the percentage.

The strongest summary comes from the Cochrane review of treatments for female pattern hair loss (van Zuuren et al., 2016). Pooling four trials with 1,006 participants that compared the two strengths, the authors concluded there was “no difference in effect between the minoxidil 2% and 5%” for total hair count or investigator-rated regrowth, and no difference in overall adverse events. The certainty of that evidence is low to moderate, so a small advantage for 5% can’t be ruled out — but a large one has not shown up in any trial.

Why the Vehicle Matters as Much as the Percentage

Minoxidil does not dissolve well in water. To get it into a liquid, solutions rely on alcohol and propylene glycol — the 2% solution label lists exactly those three inactive ingredients: alcohol, propylene glycol, and water. Keeping two and a half times as much drug in solution takes a heavier solvent base, which is where much of 5% solution’s reputation for stinging, flaking, and greasy residue comes from.

Propylene glycol is also the usual culprit when people think they are allergic to minoxidil. In a patch-testing study, Friedman et al. (2002) found that most patients with contact dermatitis from minoxidil solution were reacting to propylene glycol, not the drug, and that many could tolerate formulations made with other solvents.

That is the problem the foam was designed to solve. The 5% foam (approved for women by the FDA in February 2014, after the men’s version in 2006) delivers 5% without propylene glycol, which is a large part of why it irritates less than 5% solution. It also means trials comparing “2% vs. 5%” are often really comparing two different vehicles and two different routines at the same time.

The practical takeaway: when someone says 5% “burned” their scalp, the solvent is a likely suspect, and when someone says a product left their hair flat and greasy, the vehicle is almost always the reason. Both are fixable without changing the active ingredient.

Side Effects: Where 5% Costs More

Scalp irritation. Itching, redness, and flaking are the most common complaints with topical minoxidil, and both the Olsen and Lucky trials found them more often at 5%. With solutions, propylene glycol drives much of this. A dermatologist can patch test to tell a solvent reaction from a true minoxidil reaction.

Unwanted facial hair. This is the side effect that matters most for women. The American Academy of Dermatology lists it alongside scalp irritation as a main side effect, and it was reported more often in the 5% arm of the Lucky trial. It usually appears on the forehead, cheeks, or temples, often from product spreading via hands or pillowcases, and it typically fades after stopping.

Initial shedding. Both strengths can cause a temporary increase in shedding, which the AAD notes usually happens between weeks 2 and 8. It reflects follicles being pushed into a new growth cycle, not the treatment failing.

Systemic effects. Minoxidil began as an oral blood pressure drug, which is where concerns about the heart come from. Only a small fraction of a topical dose is absorbed through the scalp, and serious cardiovascular effects from topical use are rare. The label still tells users to stop and see a doctor for chest pain, a rapid heartbeat, faintness or dizziness, sudden weight gain, or swollen hands or feet. Rare doesn’t mean impossible, and the higher strength puts more drug on the scalp.

“Cats, in particular, are extremely sensitive to the effects of minoxidil. … Even a single lick from a contaminated pillowcase can lead to cats becoming seriously ill or even dying. Dogs can also become quite sick, but fatalities are less common.”

Adherence: The Variable Trials Don’t Capture

Clinical trials measure what minoxidil does when people use it as directed. Real life looks different. In a study of 400 patients with androgenetic alopecia, 86% had stopped using topical minoxidil, and experiencing side effects roughly tripled the odds of stopping. A separate adherence study found that people who quit had used it for a median of just 3.5 months — before minoxidil has had a fair chance to work.

This is why concentration can’t be judged on efficacy alone. Minoxidil only works while you use it, and gains fade within months of stopping. A formula that is 45% more effective in a trial but irritates your scalp enough that you quit at month three delivers less hair than a gentler one you use for years.

Retinoids are a useful comparison. Nobody starts a first-time user on 1% retinol, not because 1% doesn’t work but because the irritation makes most people give up before they see the benefit. The analogy isn’t perfect: retinoid irritation comes from the active ingredient, while much of minoxidil’s comes from the vehicle (propylene glycol). But the principle is the same — start with what you can tolerate, and step up only if you need to.

Who Should Use Which

2% is a reasonable starting point if you: are a woman starting treatment for early thinning, are concerned about unwanted facial hair, or prefer to start low. If you have a sensitive scalp or have reacted to a propylene glycol–based solution before, the formula matters more than the percentage: look for one without propylene glycol, such as 5% foam, which irritated less than 2% solution in a head-to-head trial.

5% makes more sense if you: are a man with male pattern hair loss, where 5% is the labeled standard with a measurable advantage; have moderate to advanced loss; or have used 2% consistently for 6 to 12 months without meaningful results and tolerated it well. For women who want a once-daily routine and tolerate it, 5% foam is also a well-supported option.

“Topical and oral minoxidil are generally not recommended during pregnancy or while trying to conceive.”

Either way, the AAD notes it takes 6 to 12 months to judge whether minoxidil is working. Switching strengths at month two because nothing has happened yet is switching before the evidence is in. If you’re unsure whether your hair loss is pattern hair loss at all, see a dermatologist first — telogen effluvium and other causes look similar early on and don’t respond the same way. Our guide to what to know before you start minoxidil covers the first months in more detail.

When Neither Strength Works

If 2% didn’t work after a fair trial, 5% may not either. A substantial share of people are genuine non-responders because their scalp doesn’t make enough of the enzyme that activates minoxidil — a problem more concentration doesn’t solve. For them, the better next steps are usually low-dose oral minoxidil, which is processed differently (see our comparison of topical vs. oral minoxidil), or a DHT-targeting treatment, discussed with a dermatologist.

Newer options are also worth watching. Several treatments in development take a different route than minoxidil, from an extended-release oral minoxidil designed to smooth out blood levels, to topical molecules that act on the hair follicle itself and don’t depend on the scalp enzyme that minoxidil needs. Most are still in clinical trials, so treat early results with caution, but they may give non-responders more choices in the next few years.

Verdict & Practical Implications

The most useful way to think about it: concentration is one dial, not the whole machine. The vehicle, the routine, and whether you can stick with it for a year decide results at least as much as the number on the label. For many people, especially women starting out, 2% is not the weak option. It’s the sensible first step.

References & Further Reading

• U.S. Food and Drug Administration. (2014). Women’s Rogaine 5% minoxidil topical foam, approved labeling (NDA 021812/S-009).
• DailyMed. Women’s Rogaine 5% minoxidil foam, drug label.
• DailyMed. Women’s Rogaine 2% minoxidil topical solution, drug label.
• Olsen, E. A., Dunlap, F. E., Funicella, T., et al. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology, 47(3), 377–385.
• Lucky, A. W., Piacquadio, D. J., Ditre, C. M., et al. (2004). A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Journal of the American Academy of Dermatology, 50(4), 541–553.
• Blume-Peytavi, U., Hillmann, K., Dietz, E., Canfield, D., & Garcia Bartels, N. (2011). A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology, 65(6), 1126–1134.
• van Zuuren, E. J., Fedorowicz, Z., & Schoones, J. (2016). Interventions for female pattern hair loss. Cochrane Database of Systematic Reviews, (5), CD007628.
• Friedman, E. S., Friedman, P. M., Cohen, D. E., & Washenik, K. (2002). Allergic contact dermatitis to topical minoxidil solution: etiology and treatment. Journal of the American Academy of Dermatology, 46(2), 309–312.
• Shadi, Z. (2023). Compliance to topical minoxidil and reasons for discontinuation among patients with androgenetic alopecia. Dermatology and Therapy, 13(5), 1157–1169.
• Senthilnathan, A., et al. (2023). Topical minoxidil adherence in patients with alopecia. Journal of Drugs in Dermatology, 22(3), 252–255.
• Topical minoxidil exposures and toxicoses in dogs and cats: 211 cases (2001–2019). (2021). Journal of the American Animal Hospital Association.
• Feline minoxidil toxicosis case report. PubMed Central.
• American Academy of Dermatology. Female pattern hair loss: diagnosis and treatment.
• American Academy of Dermatology. (2026). Minoxidil can be toxic to cats and dogs.
• McMullen, E., Xiong, G., Rayner, D. G., et al. (2025). Minoxidil toxicosis in cats and dogs: a scoping review and call to action. Journal of the American Academy of Dermatology, 93(2), 522–524.
• Grasso, G. M. (2026, February 5). Cats, dogs exposed to topical minoxidil can develop toxicosis. Healio.
• Queen, D. Minoxidil for hair loss: benefits, side effects & results.
• Marketing or Science. Minoxidil for Female Pattern Hair Loss.
• Marketing or Science. Why Minoxidil Doesn’t Work for Everyone.
• Marketing or Science. Topical vs. Oral Minoxidil.